| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 84,793 | 59,515 | 47,553 | 107,367 |
| Marketable securities | 29,940 | 84,726 | 114,313 | 69,944 |
| Prepaid expenses and other current assets | 3,771 | 5,498 | 8,254 | 6,647 |
| Total current assets | 118,504 | 149,739 | 170,120 | 183,958 |
| Restricted cash and deposits | 768 | 768 | 768 | 768 |
| Right-of-use assets - operating lease | 15,416 | 15,828 | 16,230 | 16,622 |
| Other long-term assets | 517 | 471 | 277 | 185 |
| Property and equipment, gross | 9,798 | 9,676 | 9,472 | NaN |
| Lessaccumulated depreciation | 7,326 | 7,052 | 6,843 | NaN |
| Property and equipment, net | 2,472 | 2,624 | 2,629 | 2,864 |
| Total assets | 137,677 | 169,430 | 190,024 | 204,397 |
| Accounts payable | 2,573 | 1,549 | 1,888 | 1,286 |
| Short-term operating lease liability | 3,267 | 3,243 | 3,220 | 3,196 |
| Accrued expenses and other current liabilities | 10,866 | 13,591 | 13,715 | 10,370 |
| Total current liabilities | 16,706 | 18,383 | 18,823 | 14,852 |
| Long-term operating lease liability | 13,724 | 14,134 | 14,534 | 14,916 |
| Total liabilities | 30,430 | 32,517 | 33,357 | 29,768 |
| Additional paid-in capital | 621,557 | 617,433 | 611,457 | 603,333 |
| Accumulated deficit | -514,103 | -480,418 | -454,859 | -428,729 |
| Accumulated other comprehensive loss | -207 | -102 | 69 | 25 |
| Total stockholders' equity | 107,247 | 136,913 | 156,667 | 174,629 |
| Total liabilities and stockholders' equity | 137,677 | 169,430 | 190,024 | 204,397 |
Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. (AURA)